Acne - Drug Pipeline Analysis and Market Forecasts to 2016

The Acne Therapeutics Market is Forecast to Show Moderate Growth in Revenues till 2016

Online PR News – 27-April-2010 – – Globaldata research suggests that the global acne market was worth $2.8 billion in 2009. It is estimated to reach revenues of $3.02 billion by 2016 at a Compound Annual Growth Rate (CAGR) of 0.7%. The moderate increase in revenues is attributed to the overcrowding of the market with generics and the increased acceptance of alternative therapies such as photodynamic therapy and Ultraviolet (UV)/blue light therapy. The current market has several products which act on acne by targeting different etiologic factors involved in the development of acne. Solodyn (minocycline hydrochloride) currently rules the acne market, followed by Doryx (doxycycline). The acne therapeutics market is witnessing a shift towards combination products, using two or more effective acne treatments. Currently marketed combination products such as Duac and Ziana are estimated to steadily increase revenues.

For more information please click or add the below link to your browser:

The acne market is primarily genericised and is moderately served by the currently marketed drugs. The majority of the pipeline products of large pharmaceutical companies also consist of combination products with very few first-in-class molecules. With emerging me-too combination products in the pipeline that are not significantly different from the current monotherapies, the acne market awaits a blockbuster drug. Increases in the population in general and an increase in the prescription rate are estimated to sustain the acne market in the future.
With the recent characterization of acne as a chronic disease, research and development (R&D) in acne therapeutics requires, if not effective new launches, immediate prioritization of research on the pathology of this seemingly simple but actually complex disease.

For more information please click or add the below link to your browser:

GlobalData assessed the current competitive landscape for acne drugs and found the competition to be strong. The market has several therapeutics for the treatment of mild, moderate and severe acne, which include antibacterials (P.acnes protein synthesis inhibitors), anti-inflammatory drugs and excessive sebum production inhibitors. Also included are drugs with selective affinity for nuclear retinoic acid receptors. Largely, treatments are based on attempts to decrease inflammatory responses, suppress bacterial growth and lower new comedone formations.

GlobalData’s report, “Acne - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global acne market. The report identifies the key trends shaping and driving the global acne market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global acne sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

For more information please click or add the below link to your browser:

Or visit our report store: